<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00422565</url>
  </required_header>
  <id_info>
    <org_study_id>2006-0137</org_study_id>
    <nct_id>NCT00422565</nct_id>
  </id_info>
  <brief_title>Zotarolimus-Versus Sirolimus-Versus PacliTaxel-Eluting Stent for Acute Myocardial Infarction Patients</brief_title>
  <acronym>ZEST-AMI</acronym>
  <official_title>Comparison of the Efficacy and Safety of Zotarolimus-Eluting Stent Versus Sirolimus-Eluting Stent Versus PacliTaxel-Eluting Stent for Acute Myocardial Infarction Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CardioVascular Research Foundation, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cordis Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CardioVascular Research Foundation, Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial has the following primary objective:&#xD;
&#xD;
      To compare the safety and effectiveness of primary acute MI intervention with ABT 578-eluting&#xD;
      balloon expandable stent (Medtronic, Minneapolis, MN) vs. sirolimus-eluting balloon&#xD;
      expandable stent (Cordis Johnson &amp; Johnson, Warren, New Jersey) vs. paclitaxel-eluting stent&#xD;
      (Taxus Liberte, Boston Scientific).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous studies have documented that a slow-release polymeric sirolimus-eluting stent&#xD;
      (Cypher, Cordis) and paclitaxel-eluting stent (Taxus, Boston Scientific) reduce neointimal&#xD;
      formation and result in decrease of angiographic restenosis and target lesion&#xD;
      revascularization at 1-3 years in the multicenter randomized clinical trials RAVEL, SIRIUS,&#xD;
      and TAXUS I-VI. From these studies, the two leading drug-eluting stents (DESs) of the Cypher&#xD;
      and Taxus have been widely and rapidly accepted as a standard treatment of coronary lesions.&#xD;
&#xD;
      Recently, randomized studies were conducted to reveal different outcomes of the different two&#xD;
      DESs. These studies showed that the sirolimus-eluting stent was better than the&#xD;
      paclitaxel-eluting stent in terms of lower angiographic restenosis rate or the two DESs were&#xD;
      similar in angiographic outcomes. A recent meta-analysis supported results of the former&#xD;
      randomized studies. Patients receiving sirolimus-eluting stent had a significantly lower risk&#xD;
      of restenosis and target vessel revascularization compared with those receiving&#xD;
      paclitaxel-eluting stent.&#xD;
&#xD;
      With a recent approval of new DES, ABT-578-eluting stent (Endeavor, Medtronic, Minneapolis,&#xD;
      MN), other comparison studies have been conducted to compare Endeavor ABT-578-eluting stent&#xD;
      with the sirolimus-eluting stent and paclitaxel-eluting stent. The ENDEAVOR clinical trials&#xD;
      are currently in progress to evaluate a phosphoryl choline (PC)-coated ABT-578-eluting stent&#xD;
      for the prevention of restenosis. Angiographic analysis at 4 months in the 100-patient focal&#xD;
      de novo lesion ENDEAVOR I feasibility study demonstrated a mean in-stent percent diameter&#xD;
      stenosis of approximately 14% and a late lumen loss of 0.3 mm with a low frequency of target&#xD;
      lesion revascularization (1%). The clinical outcomes from the ENDEAVOR II (1,197 patients&#xD;
      randomized to ABT-578 or bare metal stent) showed superior efficacy of the PC-coated&#xD;
      ABT-578-eluting stent than bare-metal stent.&#xD;
&#xD;
      In patients with acute myocardial infraction (MI), routine stent implantation has been shown&#xD;
      to have a better procedural success rate and clinical outcome than balloon angioplasty [11].&#xD;
      However, restenosis and vessel reocclusion remain major challenges limiting the long-term&#xD;
      success of percutaneous treatment.&#xD;
&#xD;
      In a clinical study of 400 patients with stent implantation in acute MI, angiographic&#xD;
      restenosis occurred in 31%, considerably more than expected for patients with stable coronary&#xD;
      disease. There is very little information available as to the efficacy and long-term safety&#xD;
      of DES in acute MI. The results from the several registry and randomized trials (Cypher-AMI,&#xD;
      Typhoon, PASSION) demonstrated the short-term or long-term safety and efficacy of DES&#xD;
      compared to BMS.&#xD;
&#xD;
      The incomplete evidence to date is that implantation of SES in patients with Acute MI is safe&#xD;
      and effective more than BMS and results of implantation of PES are at variance with the&#xD;
      results of the BMS. However, up to date, there are randomized trials to compare the efficacy&#xD;
      and safety among commonly used DES (zotarolimus- vs. sirolimus- vs. paclitaxel-eluting&#xD;
      stents) for the treatment of acute MI patients. The results of large randomized trials and&#xD;
      larger registries will allow us to make evidence-based decisions about which stent to use in&#xD;
      patients with acute MI. Therefore, we designed a randomized, controlled, partially blinded&#xD;
      trial comparing the safety and efficacy of the zotarolimus vs. sirolimus vs. paclitaxel&#xD;
      stents in acute MI patients undergoing percutaneous coronary intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The recruitment rate was much slower than expected.&#xD;
  </why_stopped>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The composite of death (all cause-mortality), MI (Q wave and non Q wave) and ischemia-driven target vessel revascularization.</measure>
    <time_frame>At 12 months after the index procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause Death</measure>
    <time_frame>1 month, 6 month, 1 year and thereafter annaully up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>1 month, 6 month, 1 year and thereafter annaully up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent Myocardial infarction</measure>
    <time_frame>1 month, 6 month, 1 year and thereafter annaully up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization (all and ischemia-driven)</measure>
    <time_frame>1 month, 6 month, 1 year and thereafter annaully up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization (all and ischemia-driven)</measure>
    <time_frame>1 month, 6 month, 1 year and thereafter annaully up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis for the patients</measure>
    <time_frame>1 month, 6 month, 1 year and thereafter annaully up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late luminal loss in both in-stent and in-segment</measure>
    <time_frame>at 8 month angiographic follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binary restenosis in both in-stent and in-segment</measure>
    <time_frame>at 8 month angiographic follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success defined as achievement of a final diameter stenosis of &lt;30% by QCA using any percutaneous method, without the occurrence of death, Q wave MI, or repeat revascularization of the target lesion</measure>
    <time_frame>during the hospital stay</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">328</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Endeavor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zotarolimus-eluting stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cypher</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sirolimus-eluting stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Taxus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel-eluting stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endeavor, Medtronic</intervention_name>
    <description>Zotarolimus-eluting stent</description>
    <arm_group_label>Endeavor</arm_group_label>
    <other_name>Zotarolimus-eluting stent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cypher, Cordis</intervention_name>
    <description>Sirolimus-eluting stent</description>
    <arm_group_label>Cypher</arm_group_label>
    <other_name>Sirolimus-eluting stent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Taxus Liberte, Boston Scientific</intervention_name>
    <description>Paclitaxel-eluting stent</description>
    <arm_group_label>Taxus</arm_group_label>
    <other_name>Paclitaxel-eluting stent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patient must be at least 18 years of age.&#xD;
&#xD;
          2. Culprit de novo lesion in a native coronary artery with significant stenosis (&gt;50% by&#xD;
             visual estimate) eligible for stent implantation (no limitation on stent length)&#xD;
&#xD;
          3. Prolonged, continuous (≥ 20 min) chest pain despite nitrate and: (1) at least 1mm&#xD;
             ST-segment elevation in at least 2 leads or reciprocal ST-segment depression ≥ 2&#xD;
             contiguous precordial leads, or (2) newly developed left bundle branch block&#xD;
&#xD;
          4. Symptoms &lt; 12 hours&#xD;
&#xD;
          5. The patient or guardian agrees to the study protocol and the schedule of clinical and&#xD;
             angiographic follow-up, and provides informed, written consent, as approved by the&#xD;
             appropriate Institutional Review Board/Ethical Committee of the respective clinical&#xD;
             site.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The patient has a known hypersensitivity or contraindication to any of the following&#xD;
             medications:&#xD;
&#xD;
               -  Heparin&#xD;
&#xD;
               -  Aspirin&#xD;
&#xD;
               -  Both Clopidogrel and TIclopidine&#xD;
&#xD;
               -  Sirolimus, paclitaxel, ABT 578&#xD;
&#xD;
               -  Stainless steel and/or&#xD;
&#xD;
               -  Contrast media (patients with documented sensitivity to contrast which can be&#xD;
                  effectively pre-medicated with steroids and diphenhydramine [e.g. rash] may be&#xD;
                  enrolled. Patients with true anaphylaxis to prior contrast media, however, should&#xD;
                  not be enrolled).&#xD;
&#xD;
          2. Systemic (intravenous) Sirolimus, paclitaxel or ABT-578 use within 12 months.&#xD;
&#xD;
          3. Female of childbearing potential, unless a recent pregnancy test is negative, who&#xD;
             possibly plan to become pregnant any time after enrollment into this study.&#xD;
&#xD;
          4. History of bleeding diathesis or known coagulopathy (including heparin-induced&#xD;
             thrombocytopenia), or will refuse blood transfusions.&#xD;
&#xD;
          5. Fibrinolytic therapy for current MI treatment&#xD;
&#xD;
          6. Previous coronary intervention on target vessel&#xD;
&#xD;
          7. Non-cardiac co-morbid conditions are present with life expectancy &lt;1 year or that may&#xD;
             result in protocol non-compliance (per site investigator's medical judgment).&#xD;
&#xD;
          8. Patients who are actively participating in another drug or device investigational&#xD;
             study, which have not completed the primary endpoint follow-up period.&#xD;
&#xD;
          9. Previously documented LVEF &lt;30%.&#xD;
&#xD;
         10. Evident cardiogenic shock before randomization&#xD;
&#xD;
         11. Patients with left main stem stenosis (&gt;50% by visual estimate)&#xD;
&#xD;
         12. Severe calcification or tortuosity&#xD;
&#xD;
         13. Multi-vessel disease with non-culprit vessel requiring bypass surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung-Jung Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Soonchunhyang University Bucheon Hospital</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic University Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>GangNeung</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHIC Ilsan Hospital</name>
      <address>
        <city>Ilsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan Natioanal University Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-732</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Catholic Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University Wonju Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <study_first_submitted>January 16, 2007</study_first_submitted>
  <study_first_submitted_qc>January 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2007</study_first_posted>
  <last_update_submitted>January 30, 2009</last_update_submitted>
  <last_update_submitted_qc>January 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2009</last_update_posted>
  <responsible_party>
    <name_title>Seung-Jung Park</name_title>
    <organization>Asan Medical Center</organization>
  </responsible_party>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Stent</keyword>
  <keyword>Myocardial Infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

